Leerink Affirms Cerulean Pharma (CERU) at 'Market Perform' Following Novartis Collab, Equity Raise
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Wall Street closes higher as investors digest earnings, megacap outlook
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Roth Capital Keeps Cerulean Pharma (CERU) at 'Buy' Amid Capital Raise, Key Collaboration with Novartis
October 19, 2016 9:09 AM EDTRoth Capital affirms Cerulean Pharma (Nasdaq: CERU) with a Buy rating and $2.50 price target following a new collaboration with Novartis and cash infusion.
The firm commented, The two events are quite important for CERU, in our belief as it removes the perceived financing overhang for the company and further highlights the NDC platform potential with... More
Cerulean Pharma (CERU) Set to Open up 100% Following News of Strategic Collaboration with Novartis
October 19, 2016 8:24 AM EDTCerulean Pharma (NASDAQ: CERU) was set to open higher by 100% following news that it entered a strategic collaboration with Novartis.
... MoreCerulean Pharma (CERU), Novartis (NVS) Enter NDC Product Collaboration
October 19, 2016 8:12 AM EDTCerulean Pharma Inc. (Nasdaq: CERU) announced that the... More
Cerulean Pharma (CERU) Enters $20M Stock Purchase Agreement at $1.25/Share
October 19, 2016 8:11 AM EDTCerulean Pharma Inc. (Nasdaq: CERU) announced that it has entered into a $20 million common stock purchase agreement (Purchase Agreement) and a registration rights agreement (Registration Rights Agreement) with... More
